HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
MK 458
a sustained release formulation of a naphthoxazine compoud with selective D-2 dopamine receptor agonism
Also Known As:
MK-458; 2H-Naphth(1,2-b)-1,4-oxazin-9-ol, 3,4,4a,5,6,10b-hexahydro-4-propyl-, hydrochloride, (4aR-trans)-
Networked:
6
relevant articles (
2
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Oxazines: 9
MK 458: 6
Related Diseases
1.
Parkinsonian Disorders (Parkinsonism)
06/01/1991 - "
Patients receiving MK-458/HPMC improved on a variety of measures of parkinsonism, compared to their baseline scores; in contrast, only trivial improvement was seen within the placebo group.
"
03/01/1992 - "
Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.
"
06/01/1991 - "
Carbidopa/levodopa improved parkinsonism to a significantly greater degree than MK-458/HPMC.
"
05/01/1992 - "
Pergolide therapy controlled parkinsonism more effectively than controlled-release MK-458.
"
05/01/1992 - "
Adjunctive treatment with the very potent and selective dopamine D-2 agonist MK-458 (controlled-release formulation) improved the control of parkinsonism in patients with fluctuating responses to levodopa therapy (with carbidopa).
"
2.
Parkinson Disease (Parkinson's Disease)
08/01/1991 - "
Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.
"
08/01/1991 - "
MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use.
"
01/01/1990 - "
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
"
06/01/1988 - "
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
"
08/01/1991 - "
Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs.
"
3.
Dyskinesias (Dyskinesia)
06/01/1988 - "
While the reduction in signs of PD was comparable to those on levodopa, MK 458 did not induce dyskinesias or dystonias.
"
05/01/1992 - "
Adjunctive treatment with controlled-release MK-458 elicited less choreiform dyskinesias than either pergolide adjunctive therapy or therapy with carbidopa-levodopa alone; this finding suggests that D-1 receptor stimulation contributes to the elicitation of medication-induced chorea.
"
4.
Vomiting
08/01/1991 - "
Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo.
"
5.
Nausea
08/01/1991 - "
Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo.
"
Related Drugs and Biologics
1.
Delayed-Action Preparations
2.
levodopa drug combination carbidopa (Nakom)
3.
Levodopa (L Dopa)
4.
Dopamine (Intropin)
5.
Carbidopa (Lodosyn)
6.
Hypromellose Derivatives
7.
naxagolide
8.
Dopamine Agents (Dopaminergic Agents)
9.
Tablets
10.
Dopamine Receptors (Dopamine Receptor)
Related Therapies and Procedures
1.
Therapeutics